Noxopharm Financial Statements From 2010 to 2025
| NOXOFDelisted Stock | USD 0.04 0.00 0.00% |
Check Noxopharm financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Noxopharm's main balance sheet or income statement drivers, such as , as well as many indicators such as . Noxopharm financial statements analysis is a perfect complement when working with Noxopharm Valuation or Volatility modules.
Noxopharm |
Noxopharm Limited Company Return On Equity Analysis
Noxopharm's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Noxopharm Return On Equity | -0.58 |
Most of Noxopharm's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Noxopharm Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Noxopharm Limited has a Return On Equity of -0.5753. This is 97.6% lower than that of the Healthcare sector and 98.42% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 85.58% higher than that of the company.
Noxopharm Limited Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Noxopharm's current stock value. Our valuation model uses many indicators to compare Noxopharm value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Noxopharm competition to find correlations between indicators driving Noxopharm's intrinsic value. More Info.Noxopharm Limited is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Noxopharm's earnings, one of the primary drivers of an investment's value.About Noxopharm Financial Statements
Noxopharm stakeholders use historical fundamental indicators, such as Noxopharm's revenue or net income, to determine how well the company is positioned to perform in the future. Although Noxopharm investors may analyze each financial statement separately, they are all interrelated. For example, changes in Noxopharm's assets and liabilities are reflected in the revenues and expenses on Noxopharm's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Noxopharm Limited. Please read more on our technical analysis and fundamental analysis pages.
Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. The company was incorporated in 2015 and is based in Chatswood, Australia. Noxopharm operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Other Consideration for investing in Noxopharm Pink Sheet
If you are still planning to invest in Noxopharm Limited check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Noxopharm's history and understand the potential risks before investing.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |